10-K
Annual Report
DAY ONE BIOPHARMACEUTICALS, INC.
DAWN
NASDAQ
CIK: 1845337
File #: 001-40431
Balance Sheet
40 line items · 2 periods
XBRL
| Item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
Current assets: | ||
Cash and cash equivalents | 197,078,000 | 124,968,000 |
Cash Equivalents | 35,578,000 | 104,838,000 |
US Treasury Securities | — | 12,947,000 |
Money Market Funds | 35,578,000 | 16,728,000 |
U.S. government agency securities | — | 75,163,000 |
Short-term investments | 244,035,000 | 406,752,000 |
Accounts receivable, net | 26,735,000 | 13,876,000 |
Inventory | 6,326,000 | 3,321,000 |
Prepaid expenses and other current assets | 10,925,000 | 13,413,000 |
Total current assets | 485,099,000 | 562,330,000 |
Property and equipment, net | 2,136,000 | 2,285,000 |
Operating lease right-of-use asset | 2,342,000 | 2,422,000 |
Intangible assets, net | 18,020,000 | 15,630,000 |
Deposits and other long-term assets | 230,000 | 121,000 |
Total assets | 507,827,000 | 582,788,000 |
Liabilities and stockholders' equity | ||
Current liabilities: | ||
Accounts payable | 3,733,000 | 3,262,000 |
Accrued expenses and other current liabilities | 54,615,000 | 68,625,000 |
Current portion of deferred revenue | 2,000,000 | 1,554,000 |
Undelivered Relapsed or Refractory, Front-Line and Companion Diagnostic Research and Development Services - License agreement with Ipsen Pharma SAS | 5,000,000 | 4,800,000 |
Current portion of operating lease liabilities | 174,000 | 10,000 |
Total current liabilities | 60,522,000 | 73,451,000 |
Long-term portion of deferred revenue | 3,040,000 | 3,233,000 |
Undelivered Relapsed or Refractory, Front-Line and Companion Diagnostic Research and Development Services - License agreement with Ipsen Pharma SAS | 5,000,000 | 4,800,000 |
Long-term portion of operating lease liabilities | 2,619,000 | 2,592,000 |
Other long-term liability | 484,000 | 761,000 |
Total liabilities | 66,665,000 | 80,037,000 |
Stockholders' equity | ||
Common stock, $0.001 par value; 500,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 102,982,700 and 101,116,162 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 10,000 | 10,000 |
Additional paid-in-capital | 1,102,490,000 | 1,056,738,000 |
Accumulated other comprehensive income | 65,000 | 84,000 |
Accumulated deficit | (661,403,000) | (554,081,000) |
Total stockholders' equity | 441,162,000 | 502,751,000 |
Common Stock | 10,000 | 10,000 |
Accumulated Other Comprehensive Loss | 65,000 | 84,000 |
Additional Paid-in Capital | 1,102,490,000 | 1,056,738,000 |
Accumulated Deficit | (661,403,000) | (554,081,000) |
Total liabilities and stockholders' equity | 507,827,000 | 582,788,000 |